Literature DB >> 24709372

Involvement of 'stress-response' kinase pathways in Alzheimer's disease progression.

Georges Mairet-Coello1, Franck Polleux2.   

Abstract

Alzheimer's disease (AD) is the most prevalent cause of dementia, affecting more than 25 million people worldwide. Current models of the pathophysiological mechanisms of AD suggest that the accumulation of soluble oligomeric forms of amyloid-β (Aβ) peptides causes early loss of excitatory synapses and impairs synaptic plasticity. The signaling pathways mediating Aβ oligomer-induced impairment of synaptic plasticity and loss of excitatory synapses are only beginning to be unraveled. Here, we review recent evidence supporting the critical contribution of conserved 'stress-response' kinase pathways in AD progression.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24709372      PMCID: PMC4122595          DOI: 10.1016/j.conb.2014.03.011

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  74 in total

1.  Neurons and plaques of Alzheimer's disease patients highly express the neuronal membrane docking protein p42IP4/centaurin alpha.

Authors:  Georg Reiser; Hans-Gert Bernstein
Journal:  Neuroreport       Date:  2002-12-20       Impact factor: 1.837

2.  Reduced activity of AMP-activated protein kinase protects against genetic models of motor neuron disease.

Authors:  M A Lim; M A Selak; Z Xiang; D Krainc; R L Neve; B C Kraemer; J L Watts; R G Kalb
Journal:  J Neurosci       Date:  2012-01-18       Impact factor: 6.167

3.  A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease.

Authors:  C A Davies; D M Mann; P Q Sumpter; P O Yates
Journal:  J Neurol Sci       Date:  1987-04       Impact factor: 3.181

4.  High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation.

Authors:  L Mucke; E Masliah; G Q Yu; M Mallory; E M Rockenstein; G Tatsuno; K Hu; D Kholodenko; K Johnson-Wood; L McConlogue
Journal:  J Neurosci       Date:  2000-06-01       Impact factor: 6.167

5.  The CAMKK2-AMPK kinase pathway mediates the synaptotoxic effects of Aβ oligomers through Tau phosphorylation.

Authors:  Georges Mairet-Coello; Julien Courchet; Simon Pieraut; Virginie Courchet; Anton Maximov; Franck Polleux
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

6.  AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism.

Authors:  Valérie Vingtdeux; Luca Giliberto; Haitian Zhao; Pallavi Chandakkar; Qingli Wu; James E Simon; Elsa M Janle; Jessica Lobo; Mario G Ferruzzi; Peter Davies; Philippe Marambaud
Journal:  J Biol Chem       Date:  2010-01-14       Impact factor: 5.157

7.  Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease.

Authors:  Jorge J Palop; Jeannie Chin; Erik D Roberson; Jun Wang; Myo T Thwin; Nga Bien-Ly; Jong Yoo; Kaitlyn O Ho; Gui-Qiu Yu; Anatol Kreitzer; Steven Finkbeiner; Jeffrey L Noebels; Lennart Mucke
Journal:  Neuron       Date:  2007-09-06       Impact factor: 17.173

8.  Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin.

Authors:  Hans Zempel; Julia Luedtke; Yatender Kumar; Jacek Biernat; Hana Dawson; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  EMBO J       Date:  2013-09-24       Impact factor: 11.598

9.  Early changes in hippocampal Eph receptors precede the onset of memory decline in mouse models of Alzheimer's disease.

Authors:  Ana María Simón; Rakel López de Maturana; Ana Ricobaraza; Luis Escribano; Lucio Schiapparelli; Mar Cuadrado-Tejedor; Alberto Pérez-Mediavilla; Jesús Avila; Joaquín Del Río; Diana Frechilla
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  JNK3 perpetuates metabolic stress induced by Aβ peptides.

Authors:  Sung Ok Yoon; Dong Ju Park; Jae Cheon Ryu; Hatice Gulcin Ozer; Chhavy Tep; Yong Jae Shin; Tae Hee Lim; Lucia Pastorino; Ajaya J Kunwar; James C Walton; Alan H Nagahara; Kun Ping Lu; Randy J Nelson; Mark H Tuszynski; Kun Huang
Journal:  Neuron       Date:  2012-09-06       Impact factor: 17.173

View more
  6 in total

Review 1.  Glia: guardians, gluttons, or guides for the maintenance of neuronal connectivity?

Authors:  Joseph Jebelli; Wei Su; Stephanie Hopkins; Jennifer Pocock; Gwenn A Garden
Journal:  Ann N Y Acad Sci       Date:  2015-03-09       Impact factor: 5.691

Review 2.  "Amyloid-beta accumulation cycle" as a prevention and/or therapy target for Alzheimer's disease.

Authors:  Chinthalapally V Rao; Adam S Asch; Daniel J J Carr; Hiroshi Y Yamada
Journal:  Aging Cell       Date:  2020-01-25       Impact factor: 9.304

3.  Aβ42 oligomers trigger synaptic loss through CAMKK2-AMPK-dependent effectors coordinating mitochondrial fission and mitophagy.

Authors:  Annie Lee; Chandana Kondapalli; Daniel M Virga; Tommy L Lewis; So Yeon Koo; Archana Ashok; Georges Mairet-Coello; Sebastien Herzig; Marc Foretz; Benoit Viollet; Reuben Shaw; Andrew Sproul; Franck Polleux
Journal:  Nat Commun       Date:  2022-08-01       Impact factor: 17.694

Review 4.  Conformational Essentials Responsible for Neurotoxicity of Aβ42 Aggregates Revealed by Antibodies against Oligomeric Aβ42.

Authors:  Chuli Song; Tianyu Zhang; Yingjiu Zhang
Journal:  Molecules       Date:  2022-10-10       Impact factor: 4.927

Review 5.  Derailed intraneuronal signalling drives pathogenesis in sporadic and familial Alzheimer's disease.

Authors:  Tom Van Dooren; Katrien Princen; Koen De Witte; Gerard Griffioen
Journal:  Biomed Res Int       Date:  2014-08-27       Impact factor: 3.411

Review 6.  Linking Mitochondria to Synapses: New Insights for Stress-Related Neuropsychiatric Disorders.

Authors:  Freddy Jeanneteau; Margarita Arango-Lievano
Journal:  Neural Plast       Date:  2016-01-14       Impact factor: 3.599

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.